Presenting an Integrated Solution for mRNA Vaccine Manufacturing

To kick off Pharma's Almanac The Road to 50 States road trip campaign, Mark Bamforth and Dave Stevens of Arranta Bio met with Nigel and the team to talk about the company's recent move into the mRNA space and how advances in manufacturing will strengthen the supply chain to meet the needs of patients.

Mark Bamforth

Mark Bamforth is the founder and President & CEO of Arranta Bio, which was established in May 2019. In 2015, Mr. Bamforth founded Brammer Bio, a viral vector CDMO supporting cell and gene therapy companies, which was acquired by Thermo Fisher Scientific in April 2019. In 2010, Mr. Bamforth founded Gallus BioPharmaceuticals, a CDMO supplying biopharmaceuticals. In September 2014, Gallus was sold to DPx Holdings B.V., which later became part of Thermo Fisher Scientific. He holds a bachelor’s degree in chemical engineering from Strathclyde University and an MBA from Henley Management College.